OrbiMed’s Ascendis Pharma A/S ASND Stock Holding History

OrbiMed’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.2M	Buy	244,456 +62,479	+34%	+$14.6M	1.21%	24
2026 Q1	$41.6M	Buy	181,977 +10,000	+6%	+$2.24M	0.83%	36
2025 Q4	$36.7M	Sell	171,977 -19,928	-10%	-$4.12M	0.75%	41
2025 Q3	$38.2M	Buy	191,905 +157,505	+458%	+$29.4M	0.9%	36
2025 Q2	$5.94M	Buy	+34,400	New	+$5.6M	0.15%	74
2021 Q3	–	Sell	-447,859	Closed	-$58.9M	–	175
2021 Q2	$58.9M	Sell	447,859 -57,300	-11%	-$7.64M	0.6%	50
2021 Q1	$65.1M	Buy	505,159 +168,659	+50%	+$25.6M	0.61%	48
2020 Q4	$56.1M	Sell	336,500 -398,000	-54%	-$65.8M	0.49%	58
2020 Q3	$113M	Sell	734,500 -828,486	-53%	-$119M	1.42%	21
2020 Q2	$231M	Sell	1,562,986 -1,724,414	-52%	-$237M	3.25%	4
2020 Q1	$370M	Sell	3,287,400 -55,700	-2%	-$7.24M	6.22%	1
2019 Q4	$465M	Sell	3,343,100 -376,073	-10%	-$41.8M	6.64%	1
2019 Q3	$358M	Sell	3,719,173 -127,500	-3%	-$14.2M	6.8%	1
2019 Q2	$443M	Sell	3,846,673 -124,000	-3%	-$14.8M	6.86%	1
2019 Q1	$467M	Sell	3,970,673 -116,700	-3%	-$10.2M	7.23%	1
2018 Q4	$256M	Sell	4,087,373 -68,518	-2%	-$4.31M	4.74%	2
2018 Q3	$294M	Sell	4,155,891 -257,400	-6%	-$17.7M	3.55%	6
2018 Q2	$294M	Buy	4,413,291 +1,045,976	+31%	+$68.8M	3.5%	6
2018 Q1	$220M	Hold	3,367,315	–	–	2.73%	9
2017 Q4	$135M	Hold	3,367,315	–	–	1.71%	17
2017 Q3	$122M	Hold	3,367,315	–	–	1.17%	28
2017 Q2	$93.5M	Buy	3,367,315 +650,000	+24%	+$17.2M	0.98%	30
2017 Q1	$76.1M	Hold	2,717,315	–	–	0.86%	38
2016 Q4	$55M	Buy	2,717,315 +526,315	+24%	+$10.5M	0.7%	45
2016 Q3	$44M	Hold	2,191,000	–	–	0.5%	56
2016 Q2	$29.1M	Buy	2,191,000 +1,968,777	+886%	+$30.3M	0.3%	65
2016 Q1	$4.12M	Hold	222,223	–	–	0.04%	121
2015 Q4	$4.07M	Hold	222,223	–	–	0.04%	110
2015 Q3	$3.93M	Sell	222,223 -1,226,768	-85%	-$23.9M	0.04%	114
2015 Q2	$25.6M	Hold	1,448,991	–	–	0.21%	77
2015 Q1	$25.1M	Buy	+1,448,991	New	+$26.3M	0.21%	74

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

OrbiMed's ASND Position: Q2 2026 in Review

OrbiMed increased its Ascendis Pharma A/S (ASND) stake by 34% in Q2 2026, buying an estimated $14.6M and bringing the position to 244,456 shares worth $65.2M. The position accounts for 1.21% of the portfolio, ranked #24.

OrbiMed first reported a position in ASND in Q1 2015 and has held it in 31 quarters since. The position peaked at $467M in Q1 2019. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

OrbiMed held 244,456 shares of Ascendis Pharma A/S worth $65.2M as of Q2 2026.
OrbiMed bought 62,479 Ascendis Pharma A/S shares in Q2 2026, an estimated $14.6M.
Ascendis Pharma A/S made up 1.21% of OrbiMed's portfolio in Q2 2026, its #24 holding.
OrbiMed first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 31 quarters since.
OrbiMed's Ascendis Pharma A/S position peaked at $467M in Q1 2019.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.